Our work in TB
The Union works towards the global elimination of TB. We support high-quality, accessible prevention and care for people with and at risk of TB, to expand the evidence base for TB care and prevention and implement new knowledge into policy and practice.
Between January 2018 and March 2020, The Union’s Project Axshya has facilitated the identification and testing of 730,000 people with presumptive TB, and the project provided sputum collection and transportation services to 320,000 people, resulting in 20,000 patients being diagnosed with TB.
Specific TB priority areas
Read more about how The Union is working to fight key areas of TB:
The Union works to develop, test, implement and scale up routine screening of child contacts of people with TB. We run observational studies and advocate to ensure children and adolescents are included in clinical trials that target diagnostics, vaccines and treatment of TB disease and infection.
The Union develops, tests, implements and scales up models of care for co-morbid conditions that increase the risk of developing TB, that are prevalent in high TB burden settings, or that adversely affect TB treatment outcomes.
The Zoonotic TB Sub-section was instrumental in the creation of the first-ever Roadmap for Zoonotic TB, a policy document that addressed the major health and economic impacts of the disease, created in collaboration with the World Health Organization.
Members work together to influence global policy and practice, ensuring their work has a greater global impact.
Tuberculosis Union news
The Centre for Operational Research at The Union, working in close collaboration with the National TB Programme and National AIDS…
The Union supports the call to action to tackle antimicrobial resistance (AMR) by the United Nations Group of Friends on AMR.
Ground-breaking Tuberculosis Psychosocial Support Guide from The Union, TB Alert and global partners
The Union in partnership with TB Alert, WHO Regional Office for Europe and the Stop TB partnership today released a new guide “…
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
In this recently accepted article for IJTLD, the authors performed a cohort-comparison study to assess Pretomanid in a regimen to treat drug-resistant TB: patients receiving the BPaL regimen had a significantly better 6-month post-treatment outcome than those on the B–L regimen. The preprint is free to read.
In this recently accepted Review for IJTLD, the authors summarise the evidence available at a country level, identifying broad mechanisms by which COVID-19 may modify TB burden and mitigation efforts.
Until recently, the focus has been on finding and treating people with TB. But now bold targets for TB prevention have been outlined in the recent UN High-Level Meeting on TB. The Union develops, tests, implements and scales up models of care to increase the uptake and completion of TB preventive treatments in key high risk groups including children under 5 and people living with HIV.
'Prevent Tuberculosis: Management of TB Infection' is a free course which improves knowledge of all aspects of the management of TB infection including the diagnosis and treatment of tuberculosis with the specific aim of increasing country-level implementation of TB prevention among i) household contact of people affected by TB, especially those under five years of age, ii) persons with risk factors to develop TB, and iii) people living with HIV in care.